AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Beucher, Julie ^a,b,c   Boëlle, Pierre Yves ^c,d   Busson, Pierre François ^d   Muselet Charlier, Céline ^a   Clement, Annick ^a,c   Corvol, Harriet ^a,c  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; LUCIFERASE; PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; AGE; AGER GENE; ARTICLE; CHILD; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENE ACTIVITY; GENE MUTATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HEIGHT; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; INFLAMMATION; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MODIFIER GENE; MORTALITY; NUCLEIC ACID BASE SUBSTITUTION; PRESCHOOL CHILD; PROMOTER REGION; RESPIRATORY TRACT INFLAMMATION;

ADOLESCENT; ADULT; CELL LINE; CHILD; CYSTIC FIBROSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENES, REPORTER; GENETIC ASSOCIATION STUDIES; HUMANS; LUCIFERASES, RENILLA; LUNG; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RECEPTORS, IMMUNOLOGIC; RESPIRATORY FUNCTION TESTS; YOUNG ADULT;

EID: 84864464525     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041913     Document Type: Article

References (23)

1. Corvol H, Fitting C, Chadelat K, Jacquot J, Tabary O, et al. (2003) Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 284: L997-1003.
2. Makam M, Diaz D, Laval J, Gernez Y, Conrad CK, et al. (2009) Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci U S A 106: 5779-83.
3. Han SH, Kim YH, Mook-Jung I (2011) RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 31: 91-7.
4. Mukherjee TK, Mukhopadhyay S, Hoidal JR (2008) Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 162: 210-5.
5. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, et al. (2006) Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008-15.
6. Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, et al. (2006) Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 323: 475-88.
7. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, et al. (2008) A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172: 583-91.
8. Wu L, Ma L, Nicholson LF, Black PN (2011) Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 105: 329-36.
9. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, et al. (2009) Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 94: 5174-80.
10. Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, et al. (2007) Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22: 2020-6.
11. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, et al. (2010) Metaanalyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 42: 45-52.
12. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, et al. (2010) Genome-wide association study identifies five loci associated with lung function. Nat Genet 42: 36-44.
13. Corvol H, Beucher J, Boelle PY, Busson PF, Muselet-Charlier C, et al. (2011) Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros.
14. Laki J, Laki I, Nemeth K, Ujhelyi R, Bede O, et al. (2006) The 8.1 ancestral MHC haplotype is associated with delayed onset of colonization in cystic fibrosis. Int Immunol 18: 1585-90.
15. Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, et al. (2011) A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. Pediatr Pulmonol 46: 857-69.
16. Bellis G, Cazes MH, Lemonnier L, Sponga M (2010) Registre Français de la Mucoviscidose. www.registredelamuco.org.
17. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B (1976) The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis 113: 587-600.
18. Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, et al. (2005) Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 172: 885-91.
19. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, et al. (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43: 539-46.
20. Hudson BI, Stickland MH, Futers TS, Grant PJ (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-11.
21. Vazzana N, Santilli F, Cuccurullo C, Davi G (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4: 389-401.
22. Saadane A, Eastman J, Berger M, Bonfield TL (2011) Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. J Inflamm (Lond) 8: 26.
23. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725-34.